Quantitative Phase Microscopy for Real-Time Clinical Determination of Drug Therapy Response in Primary and Metastatic Breast Cancer
Abstract
There are no biomarkers that can accurately predict chemotherapy response in advanced cancer patients and less than 10% of patients with a detected targetable mutation are eligible for a clinical trial. There is a need for new diagnostic methods that can accurately stratify high-risk patients to effective, FDA-approved therapies. Our current patient-derived models for assessing tumor drug response require 1-8 months to obtain drug sensitivity profiles making these impractical for patient care. In this project we will develop a functional assay with the new capability to predict cancer cell response to therapy within 2 d of sample collection in terms of both population response and single-cell heterogeneity. In year 1 we have developed the technical platform for this work which will be applied in years 2 and 3. Overall, our project will provide real-time feedback to oncologists on drug sensitivity/resistance and resistant subpopulations.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2021
- Accession Number
- AD1141234
Entities
People
- Thomas A. Zangle
Organizations
- University of Utah